Therapy

Galactofuranose Biosynthesis is Potential Drug Target for M. tuberculosis

Published in TB and Outbreaks Week, March 30th, 1998

Galactofuranose biosynthesis may be a potential drug target for the treatment of tuberculosis, according to a report from manufacturer Glaxo Wellcome and Colorado State University.

"It is evident that mycobacteria are capable of both producing galactopyranosyl residues de novo by the route of UDP-glucose 4-epimerase as well as scavenging galactose by route of galactokinase and UDP-glucose-galactose-1-phosphate uridylyltransferase," A. Weston and colleagues wrote ("Biosynthetic Origin of Mycobacterial Cell Wall Galactofuranosyl Residues," Tubercle and Lung Disease, February 1998;78(2):123-131).

The mycobacterial cell wall is a good target for new...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (1998-03-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry